At the BIA Leadership Summit, Dr Fintan Walton spoke to Ian Nicholson, CEO of Chroma Therapeutics. They discussed:
• Chroma’s deal with GSK
• the key to Chroma’s novel chemistry platform technology and the importance of having a platform when running a biotech company
• biotech funding and the importance of government support for the industry
• how deal making has changed in the last 20 years, including the relationship and negotiating power between pharma and biotech companies
• the next big thing to come out of Chroma
Chroma Therapeutics
Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders.